BDSX · Biodesix Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.55M | - | $21.77M | $20.02M | $17.96M | - | $18.15M | $17.93M | $14.82M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.29M | - | $2.99M | $3.27M | $2.87M | - | $2.55M | $2.56M | $2.04M | - |
| SG&A | $24.26M | - | $21.71M | $22.41M | $20.45M | - | $20.02M | $19.66M | $20.56M | - |
| Total Operating Expenses | $31.76M | - | $28.82M | $29.74M | $27.09M | - | $26.74M | $26.16M | $25.84M | - |
| D&A | $1.40M | - | $1.49M | $1.41M | $1.44M | - | $1.00M | $900.0K | $1.42M | - |
| Operating Income | ($6.20M) | - | ($7.05M) | ($9.72M) | ($9.14M) | - | ($8.59M) | ($8.24M) | ($11.02M) | - |
| Interest Expense | $1.98M | - | $2.04M | $1.90M | $1.69M | - | $2.04M | $1.94M | $2.53M | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - | $0 | - |
| Net Income | ($7.79M) | - | ($8.72M) | ($11.47M) | ($11.10M) | - | ($10.26M) | ($10.81M) | ($13.61M) | - |
| EPS - Basic | ($0.81) | - | ($1.16) | ($1.60) | ($1.60) | - | ($1.40) | ($1.60) | ($2.80) | - |
| EPS - Diluted | ($0.81) | - | ($1.16) | ($1.60) | ($1.60) | - | ($1.40) | ($1.60) | ($2.80) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.57M | $18.99M | $16.60M | $20.73M | $17.60M | $26.25M | $31.41M | $42.22M | $11.49M | $26.28M |
| Accounts Receivable | $9.50M | $9.04M | $12.67M | $7.45M | $7.64M | $8.60M | $8.04M | $10.13M | $9.89M | $7.68M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.65M | $3.08M | $3.62M | $2.97M | $2.92M | $2.19M | $2.54M | $2.22M | $3.21M | $2.93M |
| Current Assets | $40.91M | $32.52M | $33.40M | $32.45M | $29.62M | $39.48M | $44.02M | $57.58M | $28.48M | $39.68M |
| Total Assets | $94.64M | $87.48M | $88.72M | $87.74M | $86.24M | $97.24M | $102.74M | $115.84M | $87.20M | $99.10M |
| Current Liabilities | $14.49M | $17.44M | $18.15M | $15.16M | $13.32M | $14.32M | $12.96M | $17.55M | $31.23M | $33.42M |
| Long-term Debt | $50.00M | $50.01M | $50.01M | $50.02M | $40.02M | $40.03M | $40.04M | $40.05M | $40.06M | $40.08M |
| Total Liabilities | $85.50M | $89.94M | $90.44M | $86.60M | $75.18M | $76.37M | $74.89M | $79.58M | $92.70M | $94.52M |
| Stockholders' Equity | $9.13M | ($2.46M) | ($1.72M) | $1.14M | $11.06M | $20.88M | $27.86M | $36.26M | ($5.50M) | $4.58M |
| Retained Earnings | ($505.56M) | ($497.76M) | ($493.78M) | ($485.07M) | ($473.60M) | ($462.50M) | ($454.25M) | ($443.99M) | ($433.18M) | ($419.57M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($10.17M) | - | - | - | ($8.60M) | - | - | - | ($15.31M) | - |
| Investing Cash Flow | ($144.0K) | - | - | - | ($137.0K) | - | - | - | ($273.0K) | - |
| Financing Cash Flow | $16.90M | - | - | - | $97.0K | - | - | - | $791.0K | - |
| CapEx | $81.0K | - | - | - | $74.0K | - | - | - | $234.0K | - |
| Free Cash Flow | ($10.25M) | - | - | - | ($8.68M) | - | - | - | ($15.54M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -24.3% | - | -32.4% | -48.6% | -50.9% | - | -47.3% | -46.0% | -74.4% | - |
| EBITDA margin | -18.8% | - | -25.5% | -41.5% | -42.9% | - | -41.8% | -40.9% | -64.8% | - |
| Net margin | -30.5% | - | -40.0% | -57.3% | -61.8% | - | -56.5% | -60.3% | -91.9% | - |
| Free cash flow margin | -40.1% | - | - | - | -48.3% | - | - | - | -104.9% | - |
| FCF / Net income | 1.32 | - | - | - | 0.78 | - | - | - | 1.14 | - |
| R&D / Revenue | 12.9% | - | 13.7% | 16.3% | 16.0% | - | 14.0% | 14.3% | 13.8% | - |
| SG&A / Revenue | 94.9% | - | 99.8% | 112.0% | 113.9% | - | 110.3% | 109.7% | 138.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.2% | - | -9.8% | -13.1% | -12.9% | - | -10.0% | -9.3% | -15.6% | - |
| Return on equity | -85.3% | - | 506.2% | -1007.7% | -100.4% | - | -36.8% | -29.8% | 247.4% | - |
| Return on invested capital | -8.3% | - | - | - | -14.1% | - | - | - | -25.2% | - |
| Liquidity | ||||||||||
| Current ratio | 2.82 | 1.86 | 1.84 | 2.14 | 2.22 | 2.76 | 3.40 | 3.28 | 0.91 | 1.19 |
| Quick ratio | 2.82 | 1.86 | 1.84 | 2.14 | 2.22 | 2.76 | 3.40 | 3.28 | 0.91 | 1.19 |
| Cash ratio | 1.76 | 1.09 | 0.91 | 1.37 | 1.32 | 1.83 | 2.42 | 2.41 | 0.37 | 0.79 |
| Leverage | ||||||||||
| Debt / Equity | 5.48 | -20.29 | -29.04 | 43.95 | 3.62 | 1.92 | 1.44 | 1.10 | -7.28 | 8.75 |
| Debt / Assets | 0.53 | 0.57 | 0.56 | 0.57 | 0.46 | 0.41 | 0.39 | 0.35 | 0.46 | 0.40 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -3.1x | - | -3.5x | -5.1x | -5.4x | - | -4.2x | -4.3x | -4.4x | - |
| Equity multiplier | 10.36 | -35.49 | -51.52 | 77.10 | 7.80 | 4.66 | 3.69 | 3.19 | -15.85 | 21.64 |
| Liabilities / Assets | 0.90 | 1.03 | 1.02 | 0.99 | 0.87 | 0.79 | 0.73 | 0.69 | 1.06 | 0.95 |
| Efficiency | ||||||||||
| Asset turnover | 0.27 | - | 0.25 | 0.23 | 0.21 | - | 0.18 | 0.15 | 0.17 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 136d | - | 213d | 136d | 155d | - | 162d | 206d | 244d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 15.3x | - | - | 726.8x | 165.6x | - | 187.0x | 107.3x | - | - |
| P / S | 5.5x | - | 2.6x | 41.3x | 102.0x | - | 286.9x | 217.1x | 187.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 42.3% | - | 19.9% | 11.7% | 21.2% | - | 34.5% | 51.0% | 63.6% | - |
| Revenue CAGR (3y) | 41.3% | - | 25.1% | 22.3% | 40.0% | - | 40.6% | 14.7% | 42.7% | - |
| Revenue CAGR (5y) | 38.1% | - | 40.7% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 32.1% | - | 17.9% | -18.0% | 17.1% | - | -19.8% | 24.6% | 32.7% | - |
| Net income growth (YoY) | 29.8% | - | 15.0% | -6.1% | 18.5% | - | 6.3% | 19.1% | 27.2% | - |
| EPS growth (YoY) | 49.4% | - | 17.1% | 0.0% | 42.9% | - | -900.0% | -300.0% | -1066.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -18.1% | - | - | - | 44.2% | - | - | - | -1.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -17.4% | - | - | -96.9% | - | 355.8% | - | - | - | -77.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$88.50M totalDiagnostic Tests$79.20M · 89.5%
Development Services$9.30M · 10.5%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing BIODESIX INC against the 5 most active filers in the same SIC group.